1
Inpharma 1290 - 2 Jun 2001 IV eptifibatide has significant long-term benefits in patients with CAD (coronary artery disease) undergoing nonurgent coronary stent implantation, say investigators from the ESPRIT * trial. Results of a 6-month analysis have already been reported. ** In this multinational study, 2064 such patients were randomised to receive IV eptifibatide [‘Integrilin’] or placebo, starting immediately prior to a percutaneous coronary intervention. Among 98.1% of evaluable patients at 12 months’ follow-up, significantly fewer eptifibatide, compared with placebo, recipients had experienced the composite endpoint of death or heart attack (8 vs 12.4% of patients) or the combined endpoint of death, heart attack and target vessel revascularisation (17.5 vs 22.1% of patients). 12-month mortality was lower in the eptifibatide, compared with the placebo, group (1.4 vs 2%). * Enhanced Suppression of Platelet Receptor GP IIb/IIIa using Integrelin Therapy ** see Inpharma 1289: 16, 26 May 2001; 800861326 COR Therapeutics Inc, et al. Significant long-term benefits of Integrilin (eptifibatide) injection maintained at one year. Media Release : [3 pages], 23 May 2001. Available from: URL: http://www.corr.com 800861457 1 Inpharma 2 Jun 2001 No. 1290 1173-8324/10/1290-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

IV eptifibatide has significant long-term benefits in patients with CAD

  • View
    214

  • Download
    2

Embed Size (px)

Citation preview

Inpharma 1290 - 2 Jun 2001

■ IV eptifibatide has significant long-term benefitsin patients with CAD (coronary artery disease)undergoing nonurgent coronary stent implantation, sayinvestigators from the ESPRIT* trial. Results of a6-month analysis have already been reported.** In thismultinational study, 2064 such patients wererandomised to receive IV eptifibatide [‘Integrilin’] orplacebo, starting immediately prior to a percutaneouscoronary intervention. Among 98.1% of evaluablepatients at 12 months’ follow-up, significantly fewereptifibatide, compared with placebo, recipients hadexperienced the composite endpoint of death or heartattack (8 vs 12.4% of patients) or the combinedendpoint of death, heart attack and target vesselrevascularisation (17.5 vs 22.1% of patients).12-month mortality was lower in the eptifibatide,compared with the placebo, group (1.4 vs 2%).* Enhanced Suppression of Platelet Receptor GP IIb/IIIa usingIntegrelin Therapy** see Inpharma 1289: 16, 26 May 2001; 800861326

COR Therapeutics Inc, et al. Significant long-term benefits of Integrilin(eptifibatide) injection maintained at one year. Media Release : [3 pages], 23May 2001. Available from: URL: http://www.corr.com 800861457

1

Inpharma 2 Jun 2001 No. 12901173-8324/10/1290-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved